Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis

Psoriasis (PsO) is a chronic inflammatory dermatosis that often presents with erythematous, sharply demarcated lesions. Although psoriasis is primarily a dermatological disease, its immune-mediated pathogenesis produces systemic effects and is closely associated with various comorbid conditions such...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2024-07, Vol.17 (8), p.989
Main Authors: Campione, Elena, Zarabian, Nikkia, Cosio, Terenzio, Borselli, Cristiana, Artosi, Fabio, Cont, Riccardo, Sorge, Roberto, Shumak, Ruslana Gaeta, Costanza, Gaetana, Rivieccio, Antonia, Gaziano, Roberta, Bianchi, Luca
Format: Article
Language:English
Subjects:
apremilast
Cholesterol
comorbidities
Comorbidity
Cytokines
Dermatology
Glucose
High density lipoprotein
Insulin
Lipids
Lipoproteins
Medical history
metabolic syndrome
Metabolism
Observational studies
Patients
PDE4-inhibitor
Population
Psoriasis
Psoriatic arthritis
Statins
Tumor necrosis factor-TNF
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis (PsO) is a chronic inflammatory dermatosis that often presents with erythematous, sharply demarcated lesions. Although psoriasis is primarily a dermatological disease, its immune-mediated pathogenesis produces systemic effects and is closely associated with various comorbid conditions such as cardiovascular disease (CVD), metabolic syndrome (MetS), and diabetes mellitus type II (DMII). Apremilast, an oral phosphodiesterase 4 (PDE-4) inhibitor, has shown promise in treating moderate-to-severe psoriasis and is associated with potential cardiometabolic benefits. In a 12-month prospective observational study involving 137 patients with moderate-to-severe psoriasis, we assessed changes in psoriasis clinimetric scores and metabolic profiles from baseline (T0) to 52 weeks (T1) to evaluate the efficacy of apremilast. After 52 weeks of apremilast treatment, we documented a statistically significant decrease in low-density lipoprotein (LDL) and total cholesterol, triglycerides, and glucose levels. Our findings even suggest a potential synergistic effect among patients treated with apremilast, alongside concomitant statin and/or insulin therapy. Although the results of our study must be validated on a larger scale, the use of apremilast in the treatment of psoriatic patients with cardio-metabolic comorbidities yields promising results.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph17080989